Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07248144 plus fulvestrant versus investigator's choice everolimus-based therapy in HR-positive/HER2-negative advanced or metastatic breast cancer after prior CDK4/6 inhibitor
MOH_2025-09-10_014332Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of prifetrastat, fulvestrant, everolimus and exemestane in breast cancer (2 arms), sponsored by Pfizer. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
prifetrastatfulvestranteverolimusexemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on MOH_2025-09-10_014332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-10_014332.